Coronary artery disease is a leading cause of death in individuals with chronic spinal cord injury (SCI). However, platelets of those with SCI (n = 30) showed neither increased aggregation nor resistance to the antiaggregatory effects of prostacyclin when compared with normal controls (n = 30). Prostanoid-induced cAMP synthesis was similar in both groups. In contrast, prostacyclin, which completely inhibited the platelet-stimulated thrombin generation in normal controls, failed to do so in those with SCI. Scatchard analysis of the binding of [3H]prostaglandin El, used as a prostacyclin receptor probe, showed the presence of one high-affinity (Kd, = 8.11 +-2.80 nM; ni = 172 + 32 sites per cell) and one low-affinity (Kd2 = 1.01 + 0.3 ,uM; n2 = 1772 + 226 sites per cell) prostacyclin receptor in normal platelets. In contrast, the same analysis in subjects with SCI showed significant loss (P < 0.001) of high-affinity receptor sites (Kd1 = 6.34 ± 1.91 nM; n1 = 43 + 10 sites per cell) with no significant change in the low affinity-receptors (Kd2 = 1.22 + 0.23; n2 = 1820 + 421). Treatment of these platelets with insulin, which has been demonstrated to restore both of the high-and low-affinity prostaglandin receptor numbers to within normal ranges in coronary artery disease, increased high-affinity receptor numbers and restored the prostacyclin effect on thrombin generation. These results demonstrate that the loss of the inhibitory effect of prostacyclin on the stimulation of thrombin generation was due to the loss of platelet high-affinity prostanoid receptors, which may contribute to atherogenesis in individuals with chronic SCI.Premature coronary artery disease (CAD) is one of the major causes of death in individuals with chronic spinal cord injury (SCI) (1). Although there is a clustering of risk factors known to be associated with atherosclerosis in those with chronic SCI, the mechanism of the increased incidence of CAD in these subjects is poorly understood (2).Aggregation of platelets is critically important in the events of normal blood coagulation as well as those of thrombosis and atherosclerosis (see refs. 3 and 4 for review). The aggregation of platelets is induced by several agonists, such as ADP, L-epinephrine, collagen, or thrombin, and the process is believed to be mediated, at least in part, through intracellular formation of prostaglandin G2 and thromboxane A2 (5). Homeostasis is achieved by the countervailing effects of several humoral factors, most notably by prostacyclin (prostaglandin 12; PGI2) through the inhibition of platelet aggregation (6). The inhibition of platelet aggregation by PGI2 is achieved by increasing the intracellular level of cAMP, an effect of the prostanoid binding to specific receptors on the cell surface, which results in the activation of adenylate cyclase (7-10). It has been shown that the platelet surface contains one high-affinity, low-capacity receptor population and one low-